For the year ending 2025-11-30, NRIX had $137,030K increase in cash & cash equivalents over the period. -$263,467K in free cash flow.
| Cash Flow | 2025-11-30 |
|---|---|
| Net loss | -264,457 |
| Depreciation and amortization | 8,740 |
| Stock-based compensation | 37,965 |
| Net accretion of discount on marketable securities | 10,322 |
| Loss on disposal of property and equipment | -89 |
| Amortization of operating lease right-of-use assets | 10,116 |
| Other | 0 |
| Prepaid expenses and other assets | 6,229 |
| Accounts payable | -630 |
| Deferred revenue | -36,980 |
| Operating lease liabilities | -5,067 |
| Accrued expenses and other current liabilities | 17,310 |
| Net cash used in operating activities | -249,465 |
| Purchases of marketable securities | 455,688 |
| Maturities of marketable securities | 617,543 |
| Purchases of property and equipment | 14,002 |
| Net cash provided by (used in) investing activities | 147,853 |
| Proceeds from issuances of common stock and pre-funded warrants, net of issuance costs | 234,762 |
| Proceeds from exercise of stock options and pre-funded warrants | 1,651 |
| Proceeds from issuance of common stock under employee stock purchase plan | 2,229 |
| Proceeds from issuances of common stock in 'at the market' financing, net of issuance costs | 0 |
| Repurchase of unvested early exercised stock options | 0 |
| Net cash provided by financing activities | 238,642 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 137,030 |
| Cash and cash equivalents at beginning of period | 110,898 |
| Cash and cash equivalents at end of period | 247,928 |
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)